Terms: = Pancreatic cancer AND CDK12, KIAA0904, CRKRS, 51755, ENSG00000167258, CRK7, CRKR, Q9NYV4
14 results:
1. cdk12 is a potential biomarker for diagnosis, prognosis and immunomodulation in pan-cancer.
Lu KQ; Li ZL; Zhang Q; Yin Q; Zhang YL; Ni WJ; Jiang LZ; He W; Wang B
Sci Rep; 2024 Mar; 14(1):6574. PubMed ID: 38503865
[TBL] [Abstract] [Full Text] [Related]
2. Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer.
Peng H; Li L; Zuo C; Chen MY; Zhang X; Myers NB; Hogg GD; DeNardo DG; Goedegebuure SP; Hawkins WG; Gillanders WE
Front Immunol; 2022; 13():1039226. PubMed ID: 36569934
[TBL] [Abstract] [Full Text] [Related]
3. Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
Leibowitz BD; Dougherty BV; Bell JSK; Kapilivsky J; Michuda J; Sedgewick AJ; Munson WA; Chandra TA; Dry JR; Beaubier N; Igartua C; Taxter T
BMC Cancer; 2022 May; 22(1):587. PubMed ID: 35643464
[TBL] [Abstract] [Full Text] [Related]
4. The Molecular Landscape of Pancreatobiliary cancers for Novel Targeted Therapies From Real-World Genomic Profiling.
Umemoto K; Yamamoto H; Oikawa R; Takeda H; Doi A; Horie Y; Arai H; Ogura T; Mizukami T; Izawa N; Moore JA; Sokol ES; Sunakawa Y
J Natl Cancer Inst; 2022 Sep; 114(9):1279-1286. PubMed ID: 35583261
[TBL] [Abstract] [Full Text] [Related]
5. Control of Expression of Key Cell Cycle Enzymes Drives Cell Line-Specific Functions of CDK7 in Human PDAC Cells.
Kolloch L; Kreinest T; Meisterernst M; Oeckinghaus A
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054996
[TBL] [Abstract] [Full Text] [Related]
6. Deep Targeted Sequencing and Its Potential Implication for cancer Therapy in Chinese Patients with Gastric Adenocarcinoma.
Yu P; Wang Y; Yu Y; Wang A; Huang L; Zhang Y; Liu W; Wu H; Yao M; Du YA; Cheng X
Oncologist; 2021 May; 26(5):e756-e768. PubMed ID: 33511732
[TBL] [Abstract] [Full Text] [Related]
7. The promise and current status of cdk12/13 inhibition for the treatment of cancer.
Tadesse S; Duckett DR; Monastyrskyi A
Future Med Chem; 2021 Jan; 13(2):117-141. PubMed ID: 33295810
[TBL] [Abstract] [Full Text] [Related]
8. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
Fumet JD; Limagne E; Thibaudin M; Truntzer C; Bertaut A; Rederstorff E; Ghiringhelli F
BMC Cancer; 2020 Aug; 20(1):748. PubMed ID: 32778095
[TBL] [Abstract] [Full Text] [Related]
9. A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for pancreatic cancer.
Zhong J; Jermusyk A; Wu L; Hoskins JW; Collins I; Mocci E; Zhang M; Song L; Chung CC; Zhang T; Xiao W; Albanes D; Andreotti G; Arslan AA; Babic A; Bamlet WR; Beane-Freeman L; Berndt S; Borgida A; Bracci PM; Brais L; Brennan P; Bueno-de-Mesquita B; Buring J; Canzian F; Childs EJ; Cotterchio M; Du M; Duell EJ; Fuchs C; Gallinger S; Gaziano JM; Giles GG; Giovannucci E; Goggins M; Goodman GE; Goodman PJ; Haiman C; Hartge P; Hasan M; Helzlsouer KJ; Holly EA; Klein EA; Kogevinas M; Kurtz RJ; LeMarchand L; Malats N; Männistö S; Milne R; Neale RE; Ng K; Obazee O; Oberg AL; Orlow I; Patel AV; Peters U; Porta M; Rothman N; Scelo G; Sesso HD; Severi G; Sieri S; Silverman D; Sund M; Tjønneland A; Thornquist MD; Tobias GS; Trichopoulou A; Van Den Eeden SK; Visvanathan K; Wactawski-Wende J; Wentzensen N; White E; Yu H; Yuan C; Zeleniuch-Jacquotte A; Hoover R; Brown K; Kooperberg C; Risch HA; Jacobs EJ; Li D; Yu K; Shu XO; Chanock SJ; Wolpin BM; Stolzenberg-Solomon RZ; Chatterjee N; Klein AP; Smith JP; Kraft P; Shi J; Petersen GM; Zheng W; Amundadottir LT
J Natl Cancer Inst; 2020 Oct; 112(10):1003-1012. PubMed ID: 31917448
[TBL] [Abstract] [Full Text] [Related]
10. Molecular Underpinnings Governing Genetic Complexity of ETS-Fusion-Negative Prostate cancer.
Bhatia V; Ateeq B
Trends Mol Med; 2019 Nov; 25(11):1024-1038. PubMed ID: 31353123
[TBL] [Abstract] [Full Text] [Related]
11. The potential markers of endocrine resistance among HR+ /HER2+ breast cancer patients.
Chen K; Quan J; Yang J; Chen Z
Clin Transl Oncol; 2020 Apr; 22(4):576-584. PubMed ID: 31209793
[TBL] [Abstract] [Full Text] [Related]
12. cdk12: an emerging therapeutic target for cancer.
Lui GYL; Grandori C; Kemp CJ
J Clin Pathol; 2018 Nov; 71(11):957-962. PubMed ID: 30104286
[TBL] [Abstract] [Full Text] [Related]
13. The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors.
Parsels LA; Parsels JD; Tanska DM; Maybaum J; Lawrence TS; Morgan MA
Cell Cycle; 2018; 17(9):1076-1086. PubMed ID: 29895190
[TBL] [Abstract] [Full Text] [Related]
14. Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress.
Saini P; Li Y; Dobbelstein M
Oncotarget; 2015 May; 6(15):13072-87. PubMed ID: 25965828
[TBL] [Abstract] [Full Text] [Related]
